MedTrace Logo

Determine the Safety and Efficacy of (R,R)-Formoterol in the Treatment of Subjects With COPD

NCT00064402 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 741

Last updated 2012-02-22

No results posted yet for this study

Summary

The purpose of this study is to assess the bronchodilator effect and safety of multiple daily doses of arformoterol administered for 12 weeks as maintenance treatment in patients with COPD

Conditions

Interventions

DRUG

arformoterol tartrate inhalation solution

arformoterol 50 mcg QD

DRUG

arformoterol tartrate inhalation solution

arformoterol 25 mcg BID

DRUG

arformoterol tartrate inhalation solution

arformoterol 15 mcg BID

DRUG

Salmeterol

Salmeterol MDI 42 mcg BID

DRUG

Placebo

Placebo BID

Sponsors & Collaborators

  • Sumitomo Pharma America, Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-30
Primary Completion
2004-03-31
Completion
2004-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00064402 on ClinicalTrials.gov